levoleucovorin calcium

P1, N=52, Active, not recruiting, University Hospital, Grenoble | Recruiting --> Active, not recruiting

P3, N=1000, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting | Trial completion date: Jan 2032 --> Dec 2032

P1, N=46, Active, not recruiting, Ono Pharmaceutical Co. Ltd | Trial completion date: Nov 2024 --> Mar 2025

P2, N=43, Active, not recruiting, National Cancer Center Hospital East | Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2025 --> Aug 2026

P1, N=32, Active, not recruiting, Ono Pharmaceutical Co. Ltd | Trial completion date: May 2025 --> Dec 2026 | Trial primary completion date: May 2025 --> Dec 2026

P3, N=1000, Not yet recruiting, Janssen Research & Development, LLC

She underwent six courses of gemcitabine + nab-paclitaxel as first-line chemotherapy, 12 courses of oxaliplatin + irinotecan + levofolinate + fluorouracil as second-line chemotherapy, and five courses of albumin-suspended irinotecan + levofolinate + fluorouracil as third-line chemotherapy. She is currently alive without recurrence at 18 months postoperatively. It is extremely rare for patients with unresectable and MSI-high pancreatic cancer to successfully undergo conversion surgery after pembrolizumab treatment.

P1/2, N=91, Recruiting, NuCana plc | Trial primary completion date: Aug 2024 --> Jan 2025

P1, N=52, Recruiting, University Hospital, Grenoble | Trial completion date: Nov 2025 --> Mar 2027 | Trial primary completion date: Nov 2024 --> Mar 2026

P1, N=65, Active, not recruiting, Ono Pharmaceutical Co. Ltd | Trial completion date: Jan 2025 --> Dec 2027 | Trial primary completion date: Jan 2025 --> Dec 2027

The regimens with >20-fold cost of conventional chemotherapy were used as first-line chemotherapy in two-thirds of patients and more than half even in the elderly population with HER2-negative AGC. This finding is important for future health economic studies on drug cost-efficacy.

P1/2, N=130, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting

P1, N=40, Active, not recruiting, Ono Pharmaceutical Co. Ltd

P2, N=41, Active, not recruiting, Institut de Recherches Internationales Servier | Not yet recruiting --> Active, not recruiting

P1, N=65, Active, not recruiting, Ono Pharmaceutical Co. Ltd

P1, N=46, Active, not recruiting, Ono Pharmaceutical Co. Ltd

P1, N=32, Active, not recruiting, Ono Pharmaceutical Co. Ltd

P3, N=816, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting

P1/2, N=130, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting | Phase classification: P2 --> P1/2

P1/2, N=130, Not yet recruiting, Merck Sharp & Dohme LLC

P2, N=130, Not yet recruiting, Merck Sharp & Dohme LLC

P3, N=700, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting

P2, N=56, Active, not recruiting, Southwest Autism Research & Resource Center | Recruiting --> Active, not recruiting | N=134 --> 56 | Trial primary completion date: Jan 2025 --> Apr 2024

P1/2, N=107, Completed, NuCana plc | Recruiting --> Completed | N=225 --> 107 | Trial completion date: Nov 2023 --> Mar 2024 | Trial primary completion date: Nov 2023 --> Mar 2024

P2, N=66, Recruiting, Taiho Oncology, Inc. | N=26 --> 66

The study demonstrated an encouraging efficacy and manageable safety profile of neoadjuvant sintilimab plus FLOT in HER2-negative locally advanced G/GEJ cancer, which suggested a potential therapeutic option for this population.

P2, N=20, Completed, Asan Medical Center | Active, not recruiting --> Completed

P2, N=41, Not yet recruiting, Institut de Recherches Internationales Servier

P1, N=52, Recruiting, University Hospital, Grenoble | Not yet recruiting --> Recruiting | Trial completion date: Nov 2024 --> Nov 2025

P=N/A, N=757, Active, not recruiting, Takeda | Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025

P2, N=20, Recruiting, Fujian Cancer Hospital | Not yet recruiting --> Recruiting | Initiation date: May 2023 --> Nov 2023

Our study demonstrated prospectively that RAM plus FOLFIRI is an effective second-line treatment after anti-EGFR antibody-containing first-line therapy in RAS wild-type and left-sided mCRC. Furthermore, the results were similar for patients who were previously treated with triplet regimen.

P2, N=134, Recruiting, Southwest Autism Research & Resource Center | Active, not recruiting --> Recruiting | Trial completion date: Jul 2024 --> Jan 2025 | Trial primary completion date: Jul 2023 --> Jan 2025

In 17 cases, the departments for the preparation of cytostatics in the Czech Republic had to accept restrictions on administering the full dose of leucovorin. These restrictions consisted of reducing the dose of the injectable form of leucovorin, changing the chemotherapy regimen, administering the oral form of calcium folinate, forcing a therapeutic break, or a combination of these approaches.

P2, N=26, Recruiting, Taiho Oncology, Inc. | Not yet recruiting --> Recruiting

The parallel administration of nal-IRI and Levo-LV is clinically safe and not inferior in efficacy. Moreover, parallel administration may offer convenience to patients and healthcare workers by reducing administration time.

P2, N=26, Not yet recruiting, Taiho Oncology, Inc.

P1/2, N=225, Recruiting, NuCana plc | Trial completion date: Jun 2023 --> Nov 2023 | Trial primary completion date: Jun 2023 --> Nov 2023

P1/2, N=91, Recruiting, NuCana plc | Not yet recruiting --> Recruiting

Levoleucovorin controlled cell proliferations in MDM-MB 231 and MCF-7 cells with GI50 values of 55.91 μM and 79.20 μM respectively. Further, a dose dependent inhibition of cancer cell migration was noted along with apoptosis induction in these cells with levoleucovorin treatment.Communicated by Ramaswamy H. Sarma.

Posterior reversible encephalopathy syndrome is a clinical and imaging syndrome characterized by endothelial dysfunction, blood-brain barrier disruption, and vasogenic edema. This is the first report that posterior reversible encephalopathy syndrome is caused by a thrombocytopenia regimen, and our case highlights the pathogenic role of a thrombocytopenia regimen in posterior reversible encephalopathy syndrome. However, the association between the thrombocytopenia regimen and previous fluorouracil, leucovorin, oxaliplatin, and docetaxel regimens needs further study.

Targeting CLDN18.2 with zolbetuximab significantly prolonged progression-free survival and overall survival when combined with mFOLFOX6 versus placebo plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Zolbetuximab plus mFOLFOX6 might represent a new first-line treatment in these patients.